Literature DB >> 11689702

8p12 stem cell myeloproliferative disorder: the FOP-fibroblast growth factor receptor 1 fusion protein of the t(6;8) translocation induces cell survival mediated by mitogen-activated protein kinase and phosphatidylinositol 3-kinase/Akt/mTOR pathways.

G Guasch1, V Ollendorff, J P Borg, D Birnbaum, M J Pébusque.   

Abstract

The FOP-fibroblast growth factor receptor 1 (FGFR1) fusion protein is expressed as a consequence of a t(6;8) (q27;p12) translocation associated with a stem cell myeloproliferative disorder with lymphoma, myeloid hyperplasia and eosinophilia. In the present report, we show that the fusion of the leucine-rich N-terminal region of FOP to the catalytic domain of FGFR1 results in conversion of murine hematopoietic cell line Ba/F3 to factor-independent cell survival via an antiapoptotic effect. This survival effect is dependent upon the constitutive tyrosine phosphorylation of FOP-FGFR1. Phosphorylation of STAT1 and of STAT3, but not STAT5, is observed in cells expressing FOP-FGFR1. The survival function of FOP-FGFR1 is abrogated by mutation of the phospholipase C gamma binding site. Mitogen-activated protein kinase (MAPK) is also activated in FOP-FGFR1-expressing cells and confers cytokine-independent survival to hematopoietic cells. These results demonstrate that FOP-FGFR1 is capable of protecting cells from apoptosis by using the same effectors as the wild-type FGFR1. Furthermore, we show that FOP-FGFR1 phosphorylates phosphatidylinositol 3 (PI3)-kinase and AKT and that specific inhibitors of PI3-kinase impair its ability to promote cell survival. In addition, FOP-FGFR1-expressing cells show constitutive phosphorylation of the positive regulator of translation p70S6 kinase; this phosphorylation is inhibited by PI3-kinase and mTOR (mammalian target of rapamycin) inhibitors. These results indicate that translation control is important to mediate the cell survival effect induced by FOP-FGFR1. Finally, FOP-FGFR1 protects cells from apoptosis by survival signals including BCL2 overexpression and inactivation of caspase-9 activity. Elucidation of signaling events downstream of FOP-FGFR1 constitutive activation provides insight into the mechanism of leukemogenesis mediated by this oncogenic fusion protein.

Entities:  

Mesh:

Substances:

Year:  2001        PMID: 11689702      PMCID: PMC99978          DOI: 10.1128/MCB.21.23.8129-8142.2001

Source DB:  PubMed          Journal:  Mol Cell Biol        ISSN: 0270-7306            Impact factor:   4.272


  85 in total

Review 1.  Oncogenic kinase signalling.

Authors:  P Blume-Jensen; T Hunter
Journal:  Nature       Date:  2001-05-17       Impact factor: 49.962

Review 2.  TOR signalling and control of cell growth.

Authors:  G Thomas; M N Hall
Journal:  Curr Opin Cell Biol       Date:  1997-12       Impact factor: 8.382

Review 3.  Regulation of translation initiation by FRAP/mTOR.

Authors:  A C Gingras; B Raught; N Sonenberg
Journal:  Genes Dev       Date:  2001-04-01       Impact factor: 11.361

4.  Constitutive activation of phosphatidylinositol 3-kinase by a naturally occurring mutant epidermal growth factor receptor.

Authors:  D K Moscatello; M Holgado-Madruga; D R Emlet; R B Montgomery; A J Wong
Journal:  J Biol Chem       Date:  1998-01-02       Impact factor: 5.157

5.  Suppression of apoptosis induced by growth factor withdrawal by an oncogenic form of c-Cbl.

Authors:  E Hamilton; K M Miller; K M Helm; W Y Langdon; S M Anderson
Journal:  J Biol Chem       Date:  2000-12-11       Impact factor: 5.157

6.  Src homology 2-containing inositol 5-phosphatase 1 binds to the multifunctional docking site of c-Met and potentiates hepatocyte growth factor-induced branching tubulogenesis.

Authors:  M Stefan; A Koch; A Mancini; A Mohr; K M Weidner; H Niemann; T Tamura
Journal:  J Biol Chem       Date:  2000-11-07       Impact factor: 5.157

Review 7.  The role of tyrosine phosphorylation in proliferation and maturation of erythroid progenitor cells--signals emanating from the erythropoietin receptor.

Authors:  U Klingmüller
Journal:  Eur J Biochem       Date:  1997-11-01

8.  FGFR1 is fused with a novel zinc-finger gene, ZNF198, in the t(8;13) leukaemia/lymphoma syndrome.

Authors:  S Xiao; S R Nalabolu; J C Aster; J Ma; L Abruzzo; E S Jaffe; R Stone; S M Weissman; T J Hudson; J A Fletcher
Journal:  Nat Genet       Date:  1998-01       Impact factor: 38.330

9.  A TEL-JAK2 fusion protein with constitutive kinase activity in human leukemia.

Authors:  V Lacronique; A Boureux; V D Valle; H Poirel; C T Quang; M Mauchauffé; C Berthou; M Lessard; R Berger; J Ghysdael; O A Bernard
Journal:  Science       Date:  1997-11-14       Impact factor: 47.728

Review 10.  Signal transducers and activators of transcription as regulators of growth, apoptosis and breast development.

Authors:  J Bromberg
Journal:  Breast Cancer Res       Date:  2000-01-28       Impact factor: 6.466

View more
  16 in total

1.  Src activation plays an important key role in lymphomagenesis induced by FGFR1 fusion kinases.

Authors:  Mingqiang Ren; Haiyan Qin; Ruizhe Ren; Josephine Tidwell; John K Cowell
Journal:  Cancer Res       Date:  2011-09-21       Impact factor: 12.701

2.  Oncogenic targeting of an activated tyrosine kinase to the Golgi apparatus in a glioblastoma.

Authors:  Alan Charest; Vicky Kheifets; Julie Park; Keara Lane; Kevin McMahon; Cathy L Nutt; David Housman
Journal:  Proc Natl Acad Sci U S A       Date:  2003-01-21       Impact factor: 11.205

3.  A complex of two centrosomal proteins, CAP350 and FOP, cooperates with EB1 in microtubule anchoring.

Authors:  Xiumin Yan; Robert Habedanck; Erich A Nigg
Journal:  Mol Biol Cell       Date:  2005-11-28       Impact factor: 4.138

4.  14-3-3 Integrates prosurvival signals mediated by the AKT and MAPK pathways in ZNF198-FGFR1-transformed hematopoietic cells.

Authors:  Shaozhong Dong; Sumin Kang; Ting-Lei Gu; Sean Kardar; Haian Fu; Sagar Lonial; Hanna Jean Khoury; Fadlo Khuri; Jing Chen
Journal:  Blood       Date:  2007-03-27       Impact factor: 22.113

5.  A novel chromosomal abnormality, t(6;10)(q27;q22), found in a polycythemic potential donor for allogeneic hematopoietic stem cell transplantation.

Authors:  Hideki Mitsui; Norimitsu Saito; Atsushi Satake; Tsuyoshi Nakazawa; Takahiro Karasuno; Akira Hiraoka
Journal:  Int J Hematol       Date:  2005-07       Impact factor: 2.490

6.  Systemic mastocytosis with associated myeloproliferative neoplasm with t(8;19)(p12;q13.1) and abnormality of FGFR1: report of a unique case.

Authors:  Christina B Duckworth; Linsheng Zhang; Shiyong Li
Journal:  Int J Clin Exp Pathol       Date:  2014-01-15

7.  PKC412 inhibits the zinc finger 198-fibroblast growth factor receptor 1 fusion tyrosine kinase and is active in treatment of stem cell myeloproliferative disorder.

Authors:  Jing Chen; Daniel J Deangelo; Jeffery L Kutok; Ifor R Williams; Benjamin H Lee; Martha Wadleigh; Nicole Duclos; Sarah Cohen; Jennifer Adelsperger; Rachel Okabe; Allison Coburn; Ilene Galinsky; Brian Huntly; Pamela S Cohen; Thomas Meyer; Doriano Fabbro; Johannes Roesel; Lolita Banerji; James D Griffin; Sheng Xiao; Jonathan A Fletcher; Richard M Stone; D Gary Gilliland
Journal:  Proc Natl Acad Sci U S A       Date:  2004-09-24       Impact factor: 11.205

8.  The 8p11 myeloproliferative syndrome: review of literature and an illustrative case report.

Authors:  Ami Goradia; Michael Bayerl; Dennis Cornfield
Journal:  Int J Clin Exp Pathol       Date:  2008-01-01

9.  Myeloproliferative disorder FOP-FGFR1 fusion kinase recruits phosphoinositide-3 kinase and phospholipase Cgamma at the centrosome.

Authors:  Hélène Lelièvre; Véronique Chevrier; Anne-Marie Tassin; Daniel Birnbaum
Journal:  Mol Cancer       Date:  2008-04-15       Impact factor: 27.401

10.  Centrosome-kinase fusions promote oncogenic signaling and disrupt centrosome function in myeloproliferative neoplasms.

Authors:  Joanna Y Lee; Wan-Jen Hong; Ravindra Majeti; Tim Stearns
Journal:  PLoS One       Date:  2014-03-21       Impact factor: 3.240

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.